Sara Vieira

Ms. Sara Vieira

3B’s Research Group, I3BS – Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnolo
+1
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2024 in Phytochemistry Reviews
Verified
Journal Article
Open access
PDF file
SVSara Vieira
Sara Vieira
RRRui M. Reis
Rui M. Reis
Helena FerreiraHelena Ferreira
Helena Ferreira
Nuno M. NevesNuno M. Neves
Nuno M. Neves
The immune system is a complex and fundamental network for organism protection. A minimal unbalance in the host defense system homeostasis can originate severe repercussions in human health. Fundamentally, immune-related diseases can arise from its compromise (immunodeficiency diseases), overactivation against itself (autoimmune diseases) or harmless substances (allergies), and failure of eliminating the harmful agent (chronic inflammation). The notable advances and achievements in the immune system diseases pathophysiology have been allowing for a dramatic improvement of the available treatments. Nevertheless, they present some drawbacks, including the inappropriate benefit/risk ratio. Therefore, there is a strong and urgent need to develop effective therapeutic strategies. Nature is a valuable source of bioactive compounds that can be explored for the development of new drugs. Particularly, plants produce a broad spectrum of secondary metabolites that can be potential prototypes for innovative therapeutic agents. This review describes the immune system and the inflammatory response and examines the current knowledge of eight plants traditionally used as immunomodulatory medicines (Boswellia serrata, Echinacea purpurea, Laurus nobilis, Lavandula angustifolia, Olea europaea, Salvia officinalis, Salvia rosmarinus, and Taraxacum officinale). Moreover, the issues responsible for possible biologic readout inconsistencies (plant species, age, selected organ, developmental stage, growth conditions, geographical location, drying methods, storage conditions, solvent of extraction, and extraction method) will also be discussed. Furthermore, a detailed list of the chemical composition and the immunomodulatory mechanism of action of the bioactive compounds of the selected plant extracts are presented. This review also includes future perspectives and proposes potential new avenues for further investigation.

20 November 2020 in Antioxidants
Verified
Journal Article
Open access
PDF file
SVSara Vieira
Sara Vieira
Helena FerreiraHelena Ferreira
Helena Ferreira
Nuno M. NevesNuno M. Neves
Nuno M. Neves
Chronic inflammation is characterized by an overproduction of several inflammatory mediators (e.g., reactive species and interleukins -IL) that play a central role in numerous diseases. The available therapies are often associated with serious side effects and, consequently, the need for safer drugs is of utmost importance. A plant traditionally used in the treatment of inflammatory conditions is Salvia officinalis. Therefore, conventional maceration and infusion of its leaves were performed to obtain hydroethanolic (HE-T) and aqueous extracts (AE-T), respectively. Their efficacy was compared to soxhlet extracts, namely aqueous (AE-S), hydroethanolic (HE-S), and ethanolic extracts (EE-S). Thin-layer chromatography demonstrated the presence of rosmarinic acid, carnosol, and/or carnosic acid in the different extracts. Generally, soxhlet provided extracts with higher antioxidant activities than traditional extraction. Moreover, under an inflammatory scenario, EE-S were the most effective, followed by HE-S, HE-T, AE-T, and AE-S, in the reduction of IL-6 and TNF-α production. Interestingly, the extracts presented higher or similar anti-inflammatory activity than diclofenac, salicylic acid, and celecoxib. In conclusion, the extraction method and the solvents of extraction influenced the antioxidant activity, but mainly the anti-inflammatory activity of the extracts. Therefore, this natural resource can enable the development of effective treatments for oxidative stress and inflammatory diseases.

1 February 2022 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
SGSara Gimondi
Sara Gimondi
CGCarlos Guimarães
Carlos Guimarães
SVSara Vieira
Sara Vieira
Virgínia M.F. GonçalvesVirgínia M.F. Gonçalves
Virgínia M.F. Gonçalves
Maria Elizabeth TiritanMaria Elizabeth Tiritan
Maria Elizabeth Tiritan
Nuno M. NevesNuno M. Neves
Nuno M. Neves

9 February 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
SVSara Vieira
Sara Vieira
SGSamuel M. Gonçalves
Samuel M. Gonçalves
Virgínia M.F. GonçalvesVirgínia M.F. Gonçalves
Virgínia M.F. Gonçalves
CLCarmen P. Llaguno
Carmen P. Llaguno
FMFelipe Macías-Vázquez
Felipe Macías-Vázquez
Nuno M. NevesNuno M. Neves
Nuno M. Neves
Echinacea purpurea is traditionally used in the treatment of inflammatory diseases. Therefore, we investigated the anti-inflammatory capacity of E. purpurea dichloromethanolic (DE) and ethanolic extracts obtained from flowers and roots (R). To identify the class of compounds responsible for the strongest bioactivity, the extracts were fractionated into phenol/carboxylic acid (F1) and alkylamide fraction (F2). The chemical fingerprint of bioactive compounds in the fractions was evaluated by LC-HRMS. E. purpurea extracts and fractions significantly reduced pro-inflammatory cytokines (interleukin 6 and/or tumor necrosis factor) and reactive oxygen and nitrogen species (ROS/RNS) production by lipopolysaccharide-stimulated primary human monocyte-derived macrophages. Dichloromethanolic extract obtained from roots (DE-R) demonstrated the strongest anti-inflammatory activity. Moreover, fractions exhibited greater anti-inflammatory activity than whole extract. Indeed, alkylamides must be the main compounds responsible for the anti-inflammatory activity of extracts; thus, the fractions presenting high content of these compounds presented greater bioactivity. It was demonstrated that alkylamides exert their anti-inflammatory activity through the downregulation of the phosphorylation of p38, ERK 1/2, STAT 3, and/or NF-κB signaling pathways, and/or downregulation of cyclooxygenase 2 expression. E. purpurea extracts and fractions, mainly DE-R-F2, are promising and powerful plant-based anti-inflammatory formulations that can be further used as a basis for the treatment of inflammatory diseases.

Verified
Journal Article
Open access
PDF file
SVSara Vieira
Sara Vieira
Virgínia M.F. GonçalvesVirgínia M.F. Gonçalves
Virgínia M.F. Gonçalves
CLCarmen P. Llaguno
Carmen P. Llaguno
FMFelipe Macías-Vázquez
Felipe Macías-Vázquez
Maria Elizabeth TiritanMaria Elizabeth Tiritan
Maria Elizabeth Tiritan
Nuno M. NevesNuno M. Neves
Nuno M. Neves
Inflammatory diseases are the focus of several clinical studies, due to limitations and serious side effects of available therapies. Plant-based drugs (e.g., salicylic acid, morphine) have become landmarks in the pharmaceutical field. Therefore, we investigated the immunomodulatory effects of flowers, leaves, and roots from Echinacea purpurea. Ethanolic (EE) and dichloromethanolic extracts (DE) were obtained using the Accelerated Solvent Extractor and aqueous extracts (AE) were prepared under stirring. Their chemical fingerprint was evaluated by liquid chromatography–high resolution mass spectrometry (LC-HRMS). The pro- and anti-inflammatory effects, as well as the reduction in intracellular reactive oxygen and nitrogen species (ROS/RNS), of the different extracts were evaluated using non-stimulated and lipopolysaccharide-stimulated macrophages. Interestingly, AE were able to stimulate macrophages to produce pro-inflammatory cytokines (tumor necrosis factor -TNF-α, interleukin -IL-1β, and IL-6), and to generate ROS/RNS. Conversely, under an inflammatory scenario, all extracts reduced the amount of pro-inflammatory mediators. DE, alkylamides-enriched extracts, showed the strongest anti-inflammatory activity. Moreover, E. purpurea extracts demonstrated generally a more robust anti-inflammatory activity than clinically used anti-inflammatory drugs (dexamethasone, diclofenac, salicylic acid, and celecoxib). Therefore, E. purpurea extracts may be used to develop new effective therapeutic formulations for disorders in which the immune system is either overactive or impaired.

1 July 2018 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
SVSara Vieira
Sara Vieira
AFAlbina R. Franco
Albina R. Franco
Emanuel M. FernandesEmanuel M. Fernandes
Emanuel M. Fernandes
SASara Amorim
Sara Amorim
Helena FerreiraHelena Ferreira
Helena Ferreira
Nuno M. NevesNuno M. Neves
Nuno M. Neves